ABOUTUS

PhenoNet: 
Redefining Neurodegenerative Disease Treatment
Doctor Putting Eye Measurement
Founded in 2023, PhenoNet is advancing a pipeline of disease-modifying therapies for ALS, Alzheimer Disease, and related conditions. Our focus is on early intervention, patient profiling, and small-molecule treatments aimed at neuroinflammatory drivers of neurodegeneration.
PhenoNet: 
Redefining Neurodegenerative Disease Treatment
Doctor Putting Eye Measurement
Founded in 2023, PhenoNet is advancing a pipeline of disease-modifying therapies for ALS, Alzheimer Disease, and related conditions. Our focus is on early intervention, patient profiling, and small-molecule treatments aimed at neuroinflammatory drivers of neurodegeneration.
Doctor Putting Eye Measurement
PhenoNet: 
Redefining Neurodegenerative Disease Treatment
Founded in 2023, PhenoNet is advancing a pipeline of disease-modifying therapies for ALS, Alzheimer Disease, and related conditions. Our focus is on early intervention, patient profiling, and small-molecule treatments aimed at neuroinflammatory drivers of neurodegeneration.

SHARE

SHARE

Girl Having Eye Check Up
 Our lead investigational compound, PHENOGENE-1A, previously approved for other indications, is now being repurposed as a potential treatment for neurodegenerative diseases. The compound demonstrates a multi-pronged mechanism of action:


Stabilizes mast cells and modulates immune response
Reduces proinflammatory cytokine and chemokine release
Inhibits β-amyloid (Aβ) aggregation
Suppresses neuroinflammatory fibrosis
Promotes neurite growth and synaptic function
Girl Having Eye Check Up
Our lead investigational compound, PHENOGENE-1A, previously approved for other indications, is now being repurposed as a potential treatment for neurodegenerative diseases. The compound demonstrates a multi-pronged mechanism of action:


Stabilizes mast cells and modulates immune response
Reduces proinflammatory cytokine and chemokine release
Inhibits β-amyloid (Aβ) aggregation
Suppresses neuroinflammatory fibrosis
Promotes neurite growth and synaptic function
Our lead investigational compound, PHENOGENE-1A, previously approved for other indications, is now being repurposed as a potential treatment for neurodegenerative diseases. The compound demonstrates a multi-pronged mechanism of action:


  • Stabilizes mast cells and modulates immune response
  • Reduces proinflammatory cytokine and chemokine release
  • Inhibits β-amyloid (Aβ) aggregation
  • Suppresses neuroinflammatory fibrosis
  • Promotes neurite growth and synaptic function
Girl Having Eye Check Up

PHENOGENE-1A is currently in a Phase IIB trial in patients with early to moderate ALS. A second Phase II trial is planned in patients with Alzheimer Disease’s patients—specifically evaluating outcomes in individuals without the APOE4 gene carrier, a key genetic risk factor in AD.


Beyond PHENOGENE-1A, we are expanding our pipeline to address other neurodegenerative diseases by inhibiting neuroinflammation and enhancing neuroprotection.

PHENOGENE-1A is currently in a Phase IIB trial in patients with early to moderate ALS. A second Phase II trial is planned in patients with Alzheimer Disease’s patients—specifically evaluating outcomes in individuals without the APOE4 gene carrier, a key genetic risk factor in AD.


Beyond PHENOGENE-1A, we are expanding our pipeline to address other neurodegenerative diseases by inhibiting neuroinflammation and enhancing neuroprotection


PHENOGENE-1A is currently in a Phase IIB trial in patients with early to moderate ALS. A second Phase II trial is planned in patients with Alzheimer Disease’s patients—specifically evaluating outcomes in individuals without the APOE4 gene carrier, a key genetic risk factor in AD.



Beyond PHENOGENE-1A, we are expanding our pipeline to address other neurodegenerative diseases by inhibiting neuroinflammation and enhancing neuroprotection.